Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 7/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976 | 0.94 | GP6 (0.64) | GP6AGTR1AGTR2 | |
| SCHEMBL8172767 | 0.91 | GP6 (0.63) | GP6AGTR1AGTR2 | |
| SCHEMBL29273926 | 0.91 | GP6 (0.59) | GP6AGTR1AGTR2 | |
| SCHEMBL8836344 | 0.88 | GP6 (0.56) | GP6AGTR1AGTR2 | |
| SCHEMBL9423834 | 0.88 | GP6 (0.57) | GP6AGTR1AGTR2 | |
| SCHEMBL9423839 | 0.88 | GP6 (0.57) | GP6AGTR1AGTR2 | |
| SCHEMBL940 | 0.87 | GP6 (0.56) | GP6AGTR1AGTR2 | |
| SCHEMBL3347428 | 0.87 | GP6 (0.54) | GP6AGTR1AGTR2 | |
| SCHEMBL8912755 | 0.87 | GP6 (0.55) | GP6AGTR1AGTR2 | |
| SCHEMBL9029998 | 0.86 | AGTR2 (0.55) | GP6AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111053910-A | Composition comprising fatty acid or derivative thereof and disubstituted biphenyl derivative | 黄泳华 | 2020-04-24 | — | — | CN | claimed |
| EP-1019048-B1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME ITALIA S P A (IT) | 2004-01-21 | — | — | EP | claimed |
| US-6576652-B2 | Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension. | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2003-06-10 | — | — | US | claimed |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2002-08-22 | — | — | US | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | claimed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | claimed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | claimed |
| WO-2023181045-A1 | PROCESS FOR THE PREPARATION OF CARCINOGENIC AZIDO IMPURITIES FREE LOSARTAN AND SALTS THEREOF | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| CN-111053910-A | Composition comprising fatty acid or derivative thereof and disubstituted biphenyl derivative | 黄泳华 | 2020-04-24 | — | — | CN | disclosed |
| EP-2902385-B1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | API CORP (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-9624181-B2 | Method for producing biaryl compound | API CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9527821-B2 | Deprotection method for tetrazole compound | API CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | API CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | MLX, BMX, BRIX1 | GP6 3922/4885AGTR1 1993/4885AGTR2 954/4885 |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | AGTR2, AGTR1, REN | GP6 1436/4885AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.